CA1184121A - Traitement de l'acne et des dermatites periorales ainsi que des infections de la peau par le virus de l'herpes - Google Patents

Traitement de l'acne et des dermatites periorales ainsi que des infections de la peau par le virus de l'herpes

Info

Publication number: CA1184121A
Authority: CA; Canada
Prior art keywords: triacontanol; hydrophilic ointment; acne; dermatitis; treatment
Prior art date: 1981-11-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000414315A

Other languages

English (en)

Inventor

Lealand L. Clark

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-11-03

Filing date

1982-10-27

Publication date

1985-03-19

1982-10-27 Application filed by Individual filed Critical Individual

1985-03-19 Application granted granted Critical

1985-03-19 Publication of CA1184121A publication Critical patent/CA1184121A/fr

Status Expired legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims abstract description 60
201000004624 Dermatitis Diseases 0.000 title claims abstract description 57
206010000496 acne Diseases 0.000 title claims abstract description 42
208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 41
241001529453 unidentified herpesvirus Species 0.000 title claims abstract description 23
208000009675 Perioral Dermatitis Diseases 0.000 title claims abstract description 13
REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 claims abstract description 110
208000010668 atopic eczema Diseases 0.000 claims abstract description 38
208000009889 Herpes Simplex Diseases 0.000 claims abstract description 21
239000008311 hydrophilic ointment Substances 0.000 claims description 24
239000000203 mixture Substances 0.000 claims description 16
206010012442 Dermatitis contact Diseases 0.000 claims description 5
208000010247 contact dermatitis Diseases 0.000 claims description 5
206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 4
208000008742 seborrheic dermatitis Diseases 0.000 claims description 4
201000004681 Psoriasis Diseases 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
206010068172 Anal pruritus Diseases 0.000 claims description 2
206010012468 Dermatitis herpetiformis Diseases 0.000 claims description 2
201000009053 Neurodermatitis Diseases 0.000 claims description 2
208000009544 Pruritus Ani Diseases 0.000 claims description 2
206010048222 Xerosis Diseases 0.000 claims description 2
208000001875 irritant dermatitis Diseases 0.000 claims description 2
201000011486 lichen planus Diseases 0.000 claims description 2
239000000126 substance Substances 0.000 claims 6
208000034189 Sclerosis Diseases 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 46
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 29
208000007514 Herpes zoster Diseases 0.000 abstract description 10
239000002674 ointment Substances 0.000 abstract description 10
230000000699 topical effect Effects 0.000 abstract description 10
239000003883 ointment base Substances 0.000 abstract description 2
230000003902 lesion Effects 0.000 description 47
210000003491 skin Anatomy 0.000 description 30
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 26
241000700605 Viruses Species 0.000 description 17
208000035475 disorder Diseases 0.000 description 16
230000000694 effects Effects 0.000 description 16
201000008937 atopic dermatitis Diseases 0.000 description 15
206010012438 Dermatitis atopic Diseases 0.000 description 13
230000035876 healing Effects 0.000 description 13
201000010099 disease Diseases 0.000 description 12
208000015181 infectious disease Diseases 0.000 description 12
238000000034 method Methods 0.000 description 12
208000003251 Pruritus Diseases 0.000 description 9
208000004898 Herpes Labialis Diseases 0.000 description 8
208000002193 Pain Diseases 0.000 description 8
208000017520 skin disease Diseases 0.000 description 8
206010061218 Inflammation Diseases 0.000 description 7
235000013871 bee wax Nutrition 0.000 description 7
239000012166 beeswax Substances 0.000 description 7
230000004054 inflammatory process Effects 0.000 description 7
230000007803 itching Effects 0.000 description 7
206010067152 Oral herpes Diseases 0.000 description 6
239000003862 glucocorticoid Substances 0.000 description 6
150000002500 ions Chemical class 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
208000001688 Herpes Genitalis Diseases 0.000 description 5
239000006071 cream Substances 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
201000004946 genital herpes Diseases 0.000 description 5
230000007794 irritation Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
230000002411 adverse Effects 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 3
201000006082 Chickenpox Diseases 0.000 description 3
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 3
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 3
241000726306 Irus Species 0.000 description 3
206010033733 Papule Diseases 0.000 description 3
206010035148 Plague Diseases 0.000 description 3
206010035664 Pneumonia Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
206010037660 Pyrexia Diseases 0.000 description 3
206010037888 Rash pustular Diseases 0.000 description 3
206010046980 Varicella Diseases 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
241000607479 Yersinia pestis Species 0.000 description 3
229960004544 cortisone Drugs 0.000 description 3
210000002683 foot Anatomy 0.000 description 3
210000004392 genitalia Anatomy 0.000 description 3
201000006747 infectious mononucleosis Diseases 0.000 description 3
230000008569 process Effects 0.000 description 3
208000029561 pustule Diseases 0.000 description 3
230000008439 repair process Effects 0.000 description 3
230000035807 sensation Effects 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
-1 vitamin C Chemical compound 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010003645 Atopy Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
208000032544 Cicatrix Diseases 0.000 description 2
241000543381 Cliftonia monophylla Species 0.000 description 2
241000784713 Cupido Species 0.000 description 2
206010014198 Eczema infantile Diseases 0.000 description 2
206010073931 Genital herpes simplex Diseases 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
208000037976 chronic inflammation Diseases 0.000 description 2
230000006020 chronic inflammation Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
210000004207 dermis Anatomy 0.000 description 2
229960003276 erythromycin Drugs 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
210000004247 hand Anatomy 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
239000002085 irritant Substances 0.000 description 2
231100000021 irritant Toxicity 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
230000005906 menstruation Effects 0.000 description 2
231100001078 no known side-effect Toxicity 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 2
210000004761 scalp Anatomy 0.000 description 2
231100000241 scar Toxicity 0.000 description 2
230000037387 scars Effects 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
239000000344 soap Substances 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
101150034533 ATIC gene Proteins 0.000 description 1
206010000349 Acanthosis Diseases 0.000 description 1
241000331231 Amorphocerini gen. n. 1 DAD-2008 Species 0.000 description 1
206010003226 Arteriovenous fistula Diseases 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
101150040772 CALY gene Proteins 0.000 description 1
101100162706 Caenorhabditis elegans ani-3 gene Proteins 0.000 description 1
101100367084 Caenorhabditis elegans such-1 gene Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
241000518994 Conta Species 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
241000896693 Disa Species 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
208000035874 Excoriation Diseases 0.000 description 1
206010016275 Fear Diseases 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
101100060915 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) comF gene Proteins 0.000 description 1
206010019973 Herpes virus infection Diseases 0.000 description 1
208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
208000006877 Insect Bites and Stings Diseases 0.000 description 1
101100286668 Mus musculus Irak1bp1 gene Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
CAMYKONBWHRPDD-UHFFFAOYSA-N Phenprobamate Chemical compound NC(=O)OCCCC1=CC=CC=C1 CAMYKONBWHRPDD-UHFFFAOYSA-N 0.000 description 1
240000001987 Pyrus communis Species 0.000 description 1
101100316117 Rattus norvegicus Unc50 gene Proteins 0.000 description 1
241000612182 Rexea solandri Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
206010042496 Sunburn Diseases 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
206010046750 Urticaria papular Diseases 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
239000003908 antipruritic agent Substances 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
229940064804 betadine Drugs 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
210000001217 buttock Anatomy 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000000315 cryotherapy Methods 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
235000018927 edible plant Nutrition 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
239000003337 fertilizer Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
JCYWCSGERIELPG-UHFFFAOYSA-N imes Chemical class CC1=CC(C)=CC(C)=C1N1C=CN(C=2C(=CC(C)=CC=2C)C)[C]1 JCYWCSGERIELPG-UHFFFAOYSA-N 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000035992 intercellular communication Effects 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
125000001802 myricyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
229940127249 oral antibiotic Drugs 0.000 description 1
239000003973 paint Substances 0.000 description 1
208000008664 papular urticaria Diseases 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
208000014232 psoriasis 12 Diseases 0.000 description 1
230000003236 psychic effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
230000037390 scarring Effects 0.000 description 1
230000001932 seasonal effect Effects 0.000 description 1
210000001732 sebaceous gland Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000003068 static effect Effects 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
210000000707 wrist Anatomy 0.000 description 1

Landscapes

Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA000414315A 1981-11-03 1982-10-27 Traitement de l'acne et des dermatites periorales ainsi que des infections de la peau par le virus de l'herpes Expired CA1184121A (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date
US31807681A	1981-11-03	1981-11-03
US31797681A	1981-11-03	1981-11-03
US318,076		1981-11-03
US317,976		1981-11-03
US48219983A	1983-04-05	1983-04-05
US482,199		1983-04-05

Publications (1)

Publication Number	Publication Date
CA1184121A true CA1184121A (fr)	1985-03-19

Family

ID=27405963

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000414315A Expired CA1184121A (fr)	1981-11-03	1982-10-27	Traitement de l'acne et des dermatites periorales ainsi que des infections de la peau par le virus de l'herpes

Country Status (1)

Country	Link
CA (1)	CA1184121A (fr)

1982
- 1982-10-27 CA CA000414315A patent/CA1184121A/fr not_active Expired

Legal Events

Date	Code	Title	Description
1989-09-26	MZSU	Surrender

Publication	Publication Date	Title
ES2278393T3 (es)	2007-08-01	Tratamiento antimicrobiano del virus herpes simplex y otras enfermedades infecciosas.
US4507281A (en)	1985-03-26	Interferon-containing compositions
US4670471A (en)	1987-06-02	Treatment for inflammatory skin disease
GB2078515A (en)	1982-01-13	Topical anti-viral preparation
EP1094807B1 (fr)	2003-04-23	Vitamine e et ses esters destines a l'utilisation dans un traitement topique de pathologies des muqueuses
CN1838885A (zh)	2006-09-27	治疗皮肤的疮和损害的方法
US20100063004A1 (en)	2010-03-11	Topical pharmaceutical composition
Jones et al.	1976	Clinical trials of topical interferon therapy of ulcerative viral keratitis
US5106879A (en)	1992-04-21	Treatment for inflammatory skin disease
US6562326B1 (en)	2003-05-13	Topical composition for burn healing
CA1184121A (fr)	1985-03-19	Traitement de l'acne et des dermatites periorales ainsi que des infections de la peau par le virus de l'herpes
JPS6365050B2 (fr)	1988-12-14
EP0078533B1 (fr)	1992-10-21	Composition médicinale pour le traitenant des affections de la peau
US5977176A (en)	1999-11-02	Compositions for the treatment of warts and herpes
CA1260397B (fr)	1989-09-26	Traitement de l'acne et des dermatites periorales ainsi que des infections de la peau par le virus de l'herpes
RU2173155C1 (ru)	2001-09-10	Ранозаживляющий, противовоспалительный и противоинфекционный лекарственный препарат
US20030072828A1 (en)	2003-04-17	Natural therapeutic composition for the treatment of wounds and sores
AU2011269256B2 (en)	2014-06-12	Agent for the treatment of skin conditions
US8492443B2 (en)	2013-07-23	Treatment for herpes simplex virus and other infectious diseases
Hornstein	1991	Guidelines for topical treatment in atopic eczema
Niedelman	1948	Treatment of common skin diseases in infants and children
WO2025224482A1 (fr)	2025-10-30	Composition à base d'acmella oppositifolia et de matricaria chamomilla
JP2007308403A (ja)	2007-11-29	皮膚外用剤
GB1601796A (en)	1981-11-04	Topical composition
Stankier	1974	Diseases of the skin. Psoriasis